Below is a list of some of the research published this year that focus on eosinophil associated diseases. This is not an exhaustive list by any means, however, many of the key journals are included.
Eosinophilic Asthma
Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomised controlled trial
Pavord ID, Holliday M, Reddel HK, et al; on behalf of the Novel START Study Team. [published online March 11, 2020]. Lancet Respir Med. doi:10.1016/S2213-2600(20)30053-9
The investigators of this study concluded that the results are in line with consistent evidence demonstrating that in patients with more severe asthma, blood eosinophil counts are an independent prognostic marker of risk for disease exacerbations and a predictive biomarker of a patient’s response to inhaled corticosteroids.
In patients with severe asthma with eosinophilia in reslizumab clinical trials, high peripheral blood eosinophil levels are associated with low FEV1 reversibility.
Virchow, J.C., Hickey, L., Du, E. et al. Allergy Asthma Clin Immunol 16, 26 (2020). https://doi.org/10.1186/s13223-020-00424-2
Eosinophilic Granulomatosis with Polyangiitis
Oral corticosteroid-sparing effects of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis
Brian D. Kent, Grainne d’Ancona, Mariana Fernandes, Linda Green, Cris Roxas, Louise Thomson, Alexandra M. Nanzer, Joanne Kavanagh, Sangita Agarwal, David J. Jackson ERJ Open Research 2020 6: 00311-2019; DOI: 10.1183/23120541.00311-2019.
A study published in European Respiratory Society Open Research reports the oral corticosteroid-sparing results of patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA, aka Churg-Strauss Syndrome) who were treated with intravenous reslizumab, which is a humanized monoclonal antibody against human interleukin-5 (IL-5).
Pharmacogenetic investigation of efficacy response to mepolizumab in eosinophilic granulomatosis with polyangiitis
Condreay LD, Parham LR, Qu XA, Steinfeld J, Wechsler ME, Raby BA, Yancey SW, Ghosh S. Rheumatol Int. 2020 Feb 3. doi: 10.1007/s00296-020-04523-6.
This publication describes the treatment of patients with eosinophilic granulomatosis with polyangiitis (EGPA) with a targeted therapy called mepolizumab, a monoclonal antibody to interleukin-5 (IL-5). They found that in the patients dosed with mepolizumab, as an add-on therapy to treatment with glucocorticoids, had reduced eosinophil counts in the blood, longer remission periods and reduced relapse rates, and reduced steroid usage.
Eosinophilic granulomatosis with polyangiitis: the multifaceted spectrum of clinical manifestations at different stages of the disease.
Berti A, Boukhlal S, Groh M, Cornec D.Expert Rev Clin Immunol. 2020 Jan;16(1):51-61. doi: 10.1080/1744666X.2019.1697678. Epub 2020 Jan 17.
The authors of this paper reviewed the clinical presentation of EGPA, focusing on specific stages of the disease, such as before overt vasculitis develops, when vasculitis is diagnosed, and during long-term follow up.
“Asthma, chronic rhinosinusitis and blood eosinophilia could anticipate the overt vasculitis for years,” the authors noted in the abstract. “An atopic background may be present in a subset of patients (25-30%), while ANCA presence varies between 10 and 40%. Systemic vasculitis rapidly occurs and clinical features demonstrating vasculitis processes.(neuropathy, purpura, scleritis, alveolar hemorrhage and glomerulonephritis) develop along with systemic symptoms (50%).”
The authors also indicated that for up to 50% of patients, asthma remains severe after vasculitis resolves and there is a high incidence of isolated-asthma and rhinosinus exacerbations. “Interleukin-5 blockers seem to be promising to control the disease and to spare corticosteroids,” they further noted.
Eosinophilic Esophagitis
Exposure to Household Detergent May Be Linked to EoE 
A study recently published in Allergy indicated that “detergents may be a key environmental trigger in EoE pathogenesis.” Researchers concluded that exposure to sodium dodecyl sulfate, a common household detergent, “decreases esophageal barrier integrity, stimulates IL-33 production, and promotes epithelial hyperplasia and tissue eosinophilia.” APFED funded this groundbreaking study thanks to donations to our organization.
Clinical Severity Index Helps Guide EoE Management
Researchers from CEGIR (the Consortium of Eosinophilic Gastrointestinal Disease Researchers) have created an international consensus severity scoring index for EoE. This new simplified scoring system, called the Index of Severity for Eosinophilic Esophagitis (I-SEE), can be completed at routine clinic visits. The system can help guide practitioners in EoE management by standardizing features of disease severity beyond eosinophil counts.
Esophageal Distensibility Defines Fibrostenotic Severity in Pediatric Eosinophilic Esophagitis
Natalie V. Hoffmann, MD, Kaitlin Keeley, BS, Joshua B. Wechsler, MD, MS. Clinical Gastroenterology and Hepatology, Sept. 16, 2022
Researchers aimed to assess whether esophageal distensibility plays a role in fibrosis severity in a cohort of pediatric EoE patients who have esophageal dysfunction. Esophageal distensibility (determined by EndoFLIP) is a measure of fibrostenotic severity that can be used to clinically phenotype pediatric EoE.
Eosinophilic Oesophagitis in Denmark: Population-based Incidence and Prevalence in a Nationwide Study from 2008 to 2018
Allin, KH, Poulsen, G, Melgaard, D, Frandsen, LT, Jess, T, Krarup, AL. Eosinophilic oesophagitis in Denmark: population-based incidence and prevalence in a nationwide study from 2008 to 2018. United European Gastroenterol J. 2022; 10( 7): 642– 52. https://doi.org/10.1002/ueg2.12273
This Danish nationwide population-based study shows a three-fold increase in EoE incidence and prevalence from 2011 to 2018.
McGowan, EC, Medernach, J, Keshavarz, B, et al. Food antigen consumption and disease activity affect food-specific IgG4 levels in patients with eosinophilic esophagitis (EoE). Clin Exp Allergy. 2022; 00: 1– 9. doi: 10.1111/cea.14215
In this study, researchers found that serum sIgG4 levels to food and aeroallergen proteins were higher in patients with EoE than non-EoE controls. They also found that higher levels of milk sIgG4 were independently associated with milk consumption and the presence of sIgE to milk proteins. Additional research is needed to determine if sIgG4 plays a pathogenic role in EoE or could be used as a biomarker for EoE.
Endoscopic approach to eosinophilic esophagitis: American Society for Gastrointestinal Endoscopy Consensus ConferenceGuidelines for EoE Endoscopy
Gastrointestinal Endoscopy. August 11, 2022
A group of 20 expert clinicians and investigators recently published consensus guidance for the use of endoscopy in EoE. These guidelines provide comprehensive advice on standards for tissue sampling, assessment of disease activity, dilation, and monitoring. The full article was published in August 2022 by Gastrointestinal Endoscopy can be accessed freely online.
More Reading
Links to the journals are below. Summaries of the following studies appear in issues of EOSolutions. For subscription information, see APFED membership details.
EOSolutions Summer 2022
- Natural History of Patients Lost to Follow-up After Esophageal Food Impaction
- Linked Color Imaging May Improve Diagnostic Accuracy for EoE
- Vitamin D Supplementation Reduces IL-13–Induced Esophageal Inflammation
- Use of the Esophageal Sponge in Directing Food Reintroduction in EoE
- Salivary Microbiota Composition May Discriminate Between Patients with EoE and Non-EoE
- Gene expression and clinical outcomes after dietary treatment for eosinophilic esophagitis: a prospective study
Eosinophilic Colitis, Eosinophilic Gastritis, Eosinophilic Gastroenteritis
Clinical Features of Pediatric Eosinophilic Gastroenteritis
Kobayashi, S., Tsunoda, T., Umetsu, S., Inui, A., Fujisawa, T. and Sogo, T. (2022), Clinical Features of Pediatric Eosinophilic Gastroenteritis. Pediatrics International. Accepted Author Manuscript e15322. https://doi.org/10.1111/ped.15322
A Japanese study of eosinophilic gastroenteritis (EGE) in children sought to identify its clinical features. The study indicated that “cracked mucosa may be a specific endoscopic finding for pediatric EGE” and “elimination diet and/or anti-allergic drugs were effective in most patients with pediatric EGE.”
Molecular, endoscopic, histologic, and circulating biomarker-based diagnosis of eosinophilic gastritis: Multi-site study
J Allergy Clin Immunol. Jan. 2020 Volume 145, Issue 1, Pages 255–269
This paper describes new testing platforms for blood and tissue that may help guide clinicians to a diagnosis of eosinophilic gastritis (EG) in the future. Currently, there are no consensus guidelines to standardize diagnostic criteria for EG. This is in large part due to EG being a rare condition, which makes it challenging to study, and also because it is common for people who have EG to also have another subset of eosinophilic gastrointestinal disease. The samples analyzed by the CEGIR investigators enabled them to develop a molecular profile that correlated with findings from endoscopy and histology. Levels of eotaxin-3 in the blood were strongly associated with expression of gastric cytokine CCL26. Additional studies are needed to validate these findings before these new testing platforms could be considered for clinical use.
This paper reflects the work of the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). APFED works in concert with CEGIR to ensure the patient perspective is included in all aspects of its work. Donations to APFED enable us to provide supplemental funding to CEGIR to ensure the success of the consortium.
Eosinophilic gastrointestinal disease below the belt
J Allergy Clin Immunol. January 2020 Volume 145, Issue 1, Pages 87–89
This article from the Journal of Allergy and Clinical Immunology reviews the current state of eosinophilic gastrointestinal diseases (EGIDs) with a focus on “unmet needs, barriers, and future directions in patients with nonesophageal EGIDs.” While eosinophilic esophagitis (EoE) has been the subject of much focus and advancement, EGIDs that affect other parts of the gastrointestinal tract, including eosinophilic gastritis (EG), eosinophilic gastroenteritis (EGE), and eosinophilic colitis (EC), are poorly understood by comparison and there are no well-established guidelines for diagnosis or management.
The article concludes that: 1. Clear diagnostic criteria for EG, EGE, and EC must be established; 2. outcome measures, such as patient-reported outcomes and endoscopic and histologic assessments, need to be developed; 3. More work is required to understand pathogenesis; and 4. Longitudinal trials are needed to better understand disease mechanisms and long-term outcomes.
This paper reflects the work of the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). APFED works in concert with CEGIR to ensure the patient perspective is included in all aspects of its work. Donations to APFED enable us to provide supplemental funding to CEGIR to ensure the success of the consortium.
Hypereosinophilic Syndromes
Kuang, FL; Curtin, BF; Alao H; Klion AD; Kumar S; Khoury P; et al.
Journal of Allergy and Clinical Immunology: In Practice; April 25, 2020DOI:https://doi.org/10.1016/j.jaip.2020.04.025
Researchers set out to describe the gastrointestinal disease of patients who were categorized as having hypereosinophilic syndrome (HES) and eosinophilic gastrointestinal disease (EGID) overlap. Their research found that patients with Multisystem HES may experience isolated gastrointestinal symptoms before developing symptoms in other organs. “There are striking clinical similarities between Multisystem HES and HES/EGID overlap patients, despite differing treatment approaches,” the authors concluded.
“Moreover, Multisystem HES can present with isolated GI involvement. Larger prospective studies are needed to confirm these findings.”
The Diagnostic Work-Up of Hypereosinophilia
Wang S.A.
Pathobiology 2019;86:39–52 https://doi.org/10.1159/000489341
Excerpt from abstract: “Hypereosinophilia (HE) is defined as a persistent elevated eosinophil count of ≥1.5 × 109/L. HE can be one of the dominant manifestations of a hematopoietic myeloid neoplasm or secondary/reactive to an underlying medical condition. If a cause of HE and its associated tissue/organ damage is not determined, the condition is considered to be idiopathic hypereosinophilic syndrome (HES). The work-up of HE can be challenging due to a broad range of causes of HE that can be either reactive or neoplastic.”
Long-Term Clinical Outcomes of High-Dose Mepolizumab Treatment for Hypereosinophilic Syndrome
Fei Li Kuang, et. al.
J Allergy Clin Immunol Pract. Sep-Oct 2018;6(5):1518-1527.e5.
Excerpt from Conclusion: “This study confirms that mepolizumab is an effective and well-tolerated therapy for HES, but suggests that response is more likely in GC-responsive subjects with idiopathic or overlap forms of HES. A primary benefit of treatment is the reduction of comorbidity due to discontinuation or the reduction of conventional HES therapies. Although subjects who completely discontinued GC had the most benefit, high-dose mepolizumab was a safe and effective salvage therapy for severe, treatment-refractory HES.”
Other Publications of Interest
Advancing patient care through the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR)
J Allergy Clin Immunol. Jan. 2020 Volume 145, Issue 1, Pages 28-37.
In this rostum, investigators from CEGIR outline the progress and direction of the consortium and the multidisciplinary relationships and engagement with patient advocacy groups like APFED, the National Institutes of Health and partners from industry and academia. The article outlines CEGIRs work with eosinophilic gastrointestinal diseases, including natural history studies to promote clinical trial readiness tools, clinical trials, investigator training program, and innovative pilot studies.
This paper reflects the work of the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). APFED works in concert with CEGIR to ensure the patient perspective is included in all aspects of its work. Donations to APFED enable us to provide supplemental funding to CEGIR to ensure the success of the consortium.
Older Publications
Eosinophilic Colitis
Classification of eosinophilic disorders of the small and large intestine. Arch. 2017 Nov 10. doi: 10.1007/s00428-017-2249-1. [Epub ahead of print]
Prevalence of Eosinophilic Gastroenteritis and Colitis in a Population-Based Study, From 2012 to 2017. Clin Gastroenterol Hepatol. 2017 Nov;15(11):1733-1741. doi: 10.1016/j.cgh.2017.05.050. Epub 2017 Jun 8.
Eosinophilic Colitis-"Not as rare". Dig Liver Dis. 2017 Jul;49(7):826-828. doi: 10.1016/j.dld.2017.04.014. Epub 2017 Apr 27. No abstract available.
The pathology and causes of tissue eosinophilia in the gastrointestinal tract. Histopathology. 2017 Aug;71(2):177-199. doi: 10.1111/his.13228. Epub 2017 May 26. Review.
Intraepithelial Lymphocyte Eotaxin-2 Expression and Perineural Mast Cell Degranulation Differentiate Allergic/Eosinophilic Colitis From Classic IBD. J Pediatr Gastroenterol Nutr. 2014 May 7. [Epub ahead of print
Eosinophilic colitis is a sporadic self limited disease of middle aged people: a population-based study. Colorectal Dis. 2013 Oct 19. doi: 10.1111/codi.12464. [Epub ahead of print]
Eosinophilic Cystitis
How should eosinophilic cystitis be treated in patients with chronic granulomatous disease? Pediatr Nephrol. 2014 Jul 19. [Epub ahead of print]
Eosinophilic cystitis: treatment with intravesical steroids and oral antihistamines. BMJ Case Rep. 2013 Sep 6;2013. pii: bcr2013009327. doi: 10.1136/bcr-2013-009327.
Eosinophilic Esophagitis
Psychiatric Comorbidities and Psychiatric Medication Use Are Highly Prevalent in Patients With Eosinophilic Esophagitis and Associate With Clinical Presentation The American Journal of Gastroenterology: June 2020 - Volume 115 - Issue 6 - p 853-858 doi: 10.14309/ajg.0000000000000597
Long-term Efficacy and Tolerability of RPC4046 in an Open-Label Extension Trial of Patients With Eosinophilic Esophagitis
12 March 2020. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2020.03.036.
Randomised clinical trial: the safety and tolerability of fluticasone propionate orally disintegrating tablets versus placebo for eosinophilic oesophagitis
Aliment Pharmacol Ther. 2020 Apr;51(8):750-759. doi: 10.1111/apt.15670. Epub 2020 Mar 9.
Emerging therapies for eosinophilic esophagitis
J Allergy Clin Immunol. January 2020 Volume 145, Issue 1, Pages 38–45
Diagnosis and treatment of eosinophilic esophagitis
J Allergy Clin Immunol. January 2020 Volume 145, Issue 1, Pages 1–7
Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis
Gastroenterology. 2020 Jan;158(1):111-122.e10.
Steroids versus dietary therapy for the treatment of eosinophilic esophagitis. Curr Opin Gastroenterol. 2014 Jul;30(4):396-401. doi: 10.1097/MOG.0000000000000086.
Genome-wide association analysis of eosinophilic esophagitis provides insight into the tissue specificity of this allergic disease. Nat Genet. 2014 Aug;46(8):895-900. doi: 10.1038/ng.3033. Epub 2014 Jul 13.
Accuracy, Safety, and Tolerability of Tissue Collection by Cytosponge vs Endoscopy for Evaluation of Eosinophilic Esophagitis. Clin Gastroenterol Hepatol. 2014 Jul 2. pii: S1542-3565(14)00933-1. doi: 10.1016/j.cgh.2014.06.026. [Epub ahead of print]
Risk factors for eosinophilic esophagitis. Clin Exp Allergy. 2014 Aug;44(8):1012-9. doi: 10.1111/cea.12363.
Prevalence of esophageal motility abnormalities increases with longer disease duration in adult patients with eosinophilic esophagitis. Neurogastroenterol Motil. 2014 Jul 14. doi: 10.1111/nmo.12400. [Epub ahead of print]
Analysis and expansion of the eosinophilic esophagitis transcriptome by RNA sequencing. Genes Immun. 2014 Jun 12. doi: 10.1038/gene.2014.27. [Epub ahead of print]
Efficacy and Safety of Oral Budesonide Suspension in Pediatric Patients With Eosinophilic Esophagitis. Clin Gastroenterol Hepatol. 2014 Jun 4. pii: S1542-3565(14)00804-0. doi: 10.1016/j.cgh.2014.05.021. [Epub ahead of print]
Eosinophilic Esophagitis in Adults Is Associated With IgG4 and Not Mediated by IgE. Gastroenterology. 2014 Jun 4. pii: S0016-5085(14)00725-2. doi: 10.1053/j.gastro.2014.05.036. [Epub ahead of print]
Swallowed topical corticosteroids reduce the risk for long-lasting bolus impactions in eosinophilic esophagitis. Kuchen T, Straumann A, Safroneeva E, Romero Y, Bussmann C, Vavricka S, Netzer P, Reinhard A, Portmann S, Schoepfer AM.
Tethered confocal endomicroscopy capsule for diagnosis and monitoring of eosinophilic esophagitis. Biomed Opt Express. 2013 Dec 13;5(1):197-207. doi: 10.1364/BOE.5.000197. eCollection 2013 Dec 13.
Propofol administration is safe in adult eosinophilic esophagitis patients sensitized to egg, soy, or peanut. Allergy. 2014 Jan 21. doi: 10.1111/all.12360.[Epub ahead of print]
Dietary Elimination Therapy is an Effective Option for Adults with Eosinophilic Esophagitis.Clin Gastroenterol Hepatol. 2014 Jan 16. pii: S1542-3565(14)00052-4. doi: 10.1016/j.cgh.2013.12.034. [Epub ahead of print]
Comparison of clinical features in patients with eosinophilic esophagitis living in an urban and rural environment. Dis Esophagus. 2014 Jan 2. doi: 10.1111/dote.12164. [Epub ahead of print]
The outcome of patients with oesophageal eosinophilic infiltration after an eight-week trial of a proton pump inhibitor. Aliment Pharmacol Ther. 2013 Nov;38(10):1312-9. doi: 10.1111/apt.12513. Epub 2013 Oct 5.
Clinical and Endoscopic Characteristics do Not Reliably Differentiate PPI-Responsive Esophageal Eosinophilia and Eosinophilic Esophagitis in Patients Undergoing Upper Endoscopy: A Prospective Cohort Study. Am J Gastroenterol. 2013 Oct 22. doi: 10.1038/ajg.2013.363. [Epub ahead of print]
Causes, evaluation, and consequences of eosinophilic esophagitis. N Y Acad Sci. 2013 Oct;1300(1):110-8. doi: 10.1111/nyas.12243.
Food and aeroallergen sensitization in adult eosinophilic esophagitis. Ann Allergy Asthma Immunol. 2013 Oct;111(4):304-5. doi: 10.1016/j.anai.2013.08.003. No abstract available.
Tolerance of baked milk in patients with cow's milk-mediated eosinophilic esophagitis. J Allergy Clin Immunol. 2013 Sep 28. doi:pii: S0091-6749(13)01303-1. 10.1016/j.jaci.2013.08.017. [Epub ahead of print].
Eosinophilic Esophagitis: A Paradigm Shift for Pathology. J Clin Gastroenterol. 2013 Sep 25. [Epub ahead of print]
Eosinophilic esophagitis in brazilian pediatric patients. Clin Med Insights Pediatr. 2013 Sep 22;7:41-8. doi: 10.4137/CMPed.S12733.
Prevalence of eosinophilic esophagitis in children with refractory aerodigestive symptoms. JAMA Otolaryngol Head Neck Surg. 2013 Sep 1;139(9):903-6. doi: 10.1001/jamaoto.2013.4171.
Diet therapy for eosinophilic esophagitis: when, why and how.(Vashi R, Hirano I.) Curr Opin Gastroenterol. 2013 Jul; 29(4):407-15. doi: 10.1097/MOG.0b013e328362285d.
Development and field testing of a novel patient-reported outcome measure of dysphagia in patients with eosinophilic esophagitis. (Dellon ES, Irani AM, Hill MR, Hirano I). Aliment Pharmacol Ther. 2013 Jul 9. doi: 10.1111/apt.12413. [Epub ahead of print]
Practical management of eosinophilic esophagitis. (Davis CM). Pediatr Ann. 2013 Jul 1;42(7):128-34. doi: 10.3928/00904481-20130619-10.
Eosinophilic esophagitis: a bulk of mysteries. Dig Dis. 2013;31(1):6-9. doi: 10.1159/000347095. Epub 2013 Jun 17
Eosinophilic esophagitis treated with immunotherapy to dust mites. J Allergy Clin Immunol. 2013 Jun 10. pii: S0091-6749(13)00753-7. doi: 10.1016/j.jaci.2013.04.053. [Epub ahead of print]
Expanding the paradigm of eosinophilic esophagitis: mast cells and IL-9. J Allergy Clin Immunol. 2013 Jun;131(6):1583-5. doi: 10.1016/j.jaci.2013.04.010.(Wang YH, Hogan SP, Fulkerson PC,
Abonia JP, Rothenberg MEz0. J Allergy Clin Immunol. 2013 Jun 10. pii: S0091-6749(13)00753-7. doi: 10.1016/j.jaci.2013.04.053. [Epub ahead of print]
Eosinophilic esophagitis in adults: an update on medical management. Curr Gastroenterol Rep. 2013 Jun;15(6):324. doi: 10.1007/s11894-013-0324-6.
Psychosocial Dysfunction in Children and Adolescents with Eosinophilic Esophagitis. J Pediatr Gastroenterol Nutr. 2013 Jun 6. [Epub ahead of print]
The association between celiac disease and eosinophilic esophagitis in children and adults BMC Gastroenterol. 2013; 13: 96. Published online 2013 May 30. doi: 10.1186/1471-230X-13-96
Eosinophilic esophagitis: A practical primer for an atypical disease. JAAPA. 2013 May;26(5):54-7.
Anti-IL-5 therapy reduces mast cell and IL-9 cell numbers in pediatric patients with eosinophilic esophagitis. J Allergy Clin Immunol. 2013 Jun;131(6):1576-82. doi: 10.1016/j.jaci.2013.02.042. Epub 2013 Apr 25.
Pathogenic role of mast cells in experimental eosinophilic esophagitis. Am J Physiol Gastrointest Liver Physiol. 2013 Jun;304(12):G1087-94. doi: 10.1152/ajpgi.00070.2013. Epub 2013 Apr 18.
Clinical analysis of primary eosinophilic esophagitis. J Neurogastroenterol Motil. 2013 Apr;19(2):204-9. doi: 10.5056/jnm.2013.19.2.204. Epub 2013 Apr 16.
Clinical manifestations, treatment, and outcomes of children and adolescents with eosinophilic esophagitis.J Pediatr (Rio J). 2013 Mar-Apr;89(2):197-203. doi: 10.1016/j.jped.2013.03.001
Incidence and Prevalence of Eosinophilic Esophagitis in Children: Systematic Review and Meta-Analysis. J Pediatr Gastroenterol Nutr. 2013 Mar 26. [Epub ahead of print]
Early Life Exposures as Risk Factors For Pediatric Eosinophilic Esophagitis: A Pilot and Feasibility Study. J Pediatr Gastroenterol Nutr. 2013 Mar 19. [Epub ahead of print]
Expression microarray analysis identifies novel epithelial-derived protein markers in eosinophilic esophagitis.Mod Pathol. 2013 Mar 15. doi: 10.1038/modpathol.2013.41. [Epub ahead of print]
The Management of Eosinophilic Esophagitis in Adults.J Clin Gastroenterol. 2013 Mar 15. [Epub ahead of print]
PedsQL™ Eosinophilic Esophagitis Module: Feasibility, Reliability and Validity. J Pediatr Gastroenterol Nutr. 2013 Mar 8. [Epub ahead of print]
Functional luminal imaging probe topography: an improved method for characterizing esophageal distensibility in eosinophilic esophagitis. Therap Adv Gastroenterol. 2013 Mar;6 (2):97-107. doi: 10.1177/1756283X12470017.
New diagnostic and therapeutic frontiers in eosinophilic esophagitis. Minerva Gastroenterol Dietol. 2013 Mar;59(1):59-68.
T Cell Co-Stimulatory Molecules: A Co-conspirator in the Pathogenesis of Eosinophilic Esophagitis? Dig Dis Sci. 2013 Mar 2. [Epub ahead of print]
Effect of proton pump inhibitor on esophageal eosinophilia. J Pediatr Gastroenterol Nutr. 2013 Feb;56(2):166-72. doi: 10.1097/MPG.0b013e3182716b7a.
Esophageal human β-defensin expression in eosinophilic esophagitis. Pediatr Res.2013 Feb 5. doi: 10.1038/pr.2013.23. [Epub ahead of print]
The role of allergy evaluation in children with eosinophilic esophagitis. J Gastroenterol. 2013 Jan 11. [Epub ahead of print]
Eosinophilic Fasciitis
Serum levels of matrix metalloproteinase-13 in patients with eosinophilic fasciitis. J Dermatol. 2014 Jul 16. doi: 10.1111/1346-8138.12563.
A57: four prolonged cases of eosinophilic fasciitis in children. Arthritis Rheumatol. 2014 Mar;66 Suppl 11:S85. doi: 10.1002/art.38473.
Delayed Diagnosis of Eosinophilic Fasciitis: A case report and review of the literature. Acta Reumatol Port. 2014 Jan 8.
Groove sign in eosinophilic fasciitis. Lancet. 2014 Jul 17. pii: S0140-6736(14)60526-2. doi: 10.1016/S0140-6736(14)60526-2. [Epub ahead of print]
Diagnosis and classification of eosinophilic fasciitis. PAutoimmun Rev. 2014 Jan 11. pii: S1568-9972(14)00031-7. doi: 10.1016/j.autrev.2014.01.019. [Epub ahead of print]
Ultrasound assessment of subcutaneous compressibility: a potential adjunctive diagnostic tool in eosinophilic fasciitis. J Clin Rheumatol. 2013 Oct;19(7):382-5. doi: 10.1097/RHU.0000000000000020.
Eosinophilic fasciitis in siblings. (Sullivan C, Coughlan R.) J Rheumatol. 2013 Jan;40(1):105. doi: 10.3899/jrheum.120936.
Eosinophilic Gastritis
Eosinophilic Gastritis in Children: Clinicopathological Correlation, Disease Course, and Response to Therapy. Ko HM, Morotti RA, Yershov O, Chehade M. Am J Gastroenterol. 2014 Jun 24. doi: 10.1038/ajg.2014.166. [Epub ahead of print]
Eosinophilic Gastroenteritis
Eosinophilic gastroenteritis associated with allergic asthma and atopic eczema. Chin Med J (Engl). 2014;127(1):192.
Eosinophilic gastroenteritis and related eosinophilic disorders. Gastroenterol Clin North Am. 2014 Jun;43(2):317-27. doi: 10.1016/j.gtc.2014.02.013.
Eosinophilic gastroenteritis treated with a multiple-food elimination diet. Allergol Int. 2014 May;63 Suppl 1:53-6. doi: 10.2332/allergolint.13-LE-0633.
Eosinophilic gastroenteritis with involvement of the urinary bladder. Pediatr Radiol. 2014 May 18. [Epub ahead of print]
Limited role of allergy testing in patients with eosinophilic gastrointestinal disorders. (Ishimura N, Furuta K,, et.al) J Gastroenterol Hepatol. 2013 Mar 11. doi: 10.1111/jgh.12197. [Epub ahead of print]
Eosinophilic gastroenteritis: review of a rare and treatable disease of the gastrointestinal tract. Case Rep Gastroenterol. 2013 Jul 16;7(2):293-8. doi: 10.1159/000354147.
Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss)
A nationwide survey on the epidemiology and clinical features of eosinophilic granulomatosis with polyangiitis (Churg-Strauss) in Japan. 2014 Jul;24(4):640-4. doi: 10.3109/14397595.2013.857582. Epub 2013 Dec 2.
Diagnosis and classification of eosinophilic granulomatosis with polyangiitis (formerly named Churg-Strauss syndrome). 2014 Feb-Mar;48-49:99-103. doi: 10.1016/j.jaut.2014.01.018. Epub 2014 Feb 12.
The molecular and functional characterization of clonally expanded CD8+ TCR BV T cells in eosinophilic granulomatosis with polyangiitis (EGPA). A. Clin Immunol. 2014 May-Jun;152(1-2):152-63. doi: 10.1016/j.clim.2014.03.001. Epub 2014 Mar 13.
Missing the beat: arrhythmia as a presenting feature of eosinophilic granulomatosis with polyangiitis. Sharpley FA. BMJ Case Rep. 2014 May 8;2014. pii: bcr2013203413. doi: 10.1136/bcr-2013-203413.
ANCA-positive and ANCA-negative phenotypes of eosinophilic granulomatosis with polyangiitis (EGPA): outcome and long-term follow-up of 50 patients from a single Polish center. J. Clin Exp Rheumatol. 2014 May-Jun;32(3 Suppl 82):S41-7. Epub 2014 May 16.
Is there a role for imatinib mesylate in the treatment of eosinophilic granulomatosis with polyangiitis? Joint Bone Spine. 2014 Jul 21. pii: S1297-319X(14)00152-3. doi: 10.1016/j.jbspin.2014.06.004. [Epub ahead of print]
Cardiac tamponade leading to the diagnosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome): a case report and review of the literature. Heart Vessels. 2014 Jul 29.
Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): evolutions in classification, etiopathogenesis, assessment and management. J. Curr Opin Rheumatol. 2014 Jan;26(1):16-23. doi: 10.1097/BOR.0000000000000015.
Anterior ischaemic optic neuropathy in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome): a case report and review of the literature. Clin Exp Rheumatol. 2013 Oct 21. [Epub ahead of print]
Can ANCA differentiate eosinophilic granulomatosis with polyangiitis (Churg-Strauss) from idiopathic hypereosinophilic syndrome? Clin Exp Rheumatol. 2013 Oct 17. [Epub ahead of print]
Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). Arthritis Res Ther. 2013 Sep 24;15(5):R133. doi: 10.1186/ar4313.
Eosinophilic Pneumonia
Acute eosinophilic pneumonia following secondhand cigarette smoke exposure. Chung MK, Lee SJ, Kim MY, Lee JH, Chang JH, Sim SS, Ryu YJ. Tuberc Respir Dis (Seoul). 2014 Apr;76(4):188-91. doi: 10.4046/trd.2014.76.4.188. Epub 2014 Apr 25.
Significance of fractional exhaled nitric oxide in chronic eosinophilic pneumonia: a retrospective cohort study. Park JY, Lee T, Lee H, Lee YJ, Park JS, Cho YJ, Yoon HI, Lee JH, Lee CT. BMC Pulm Med. 2014 May 12;14:81. doi: 10.1186/1471-2466-14-81.
Clinical implications of initial peripheral eosinophilia in acute eosinophilic pneumonia. Jhun BW, Kim SJ, Kim K, Lee JE. Respirology. 2014 Jul 2. doi: 10.1111/resp.12342. [Epub ahead of print]
Elevated concentrations of CCR7 ligands in patients with eosinophilic pneumonia. Nureki S, Miyazaki E, Ishi T, Ito T, Takenaka R, Ando M, Kumamoto T. Allergy. 2013 Sep 21. doi: 10.1111/all.12243. [Epub ahead of print]
Acute eosinophilic pneumonia occurring in a dedicator of cytokinesis 8 (DOCK8) deficient patient. Tsuge I, Ito K, Ohye T, Kando N, Kondo Y, Nakajima Y, Inuo C, Kurahashi H, Urisu A. Pediatr Pulmonol. 2013 Sep 18. doi: 10.1002/ppul.22814. [Epub ahead of print]
Other Publications of Interest
Advancing patient care through the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR)
J Allergy Clin Immunol. Jan. 2020 Volume 145, Issue 1, Pages 28-37.